Top Markets
Coin of the day
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
Rang in aandelen #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Aandeelprijs
$5.34
Laatst gesynchroniseerd: 2026-08-14
Marktkapitalisatie
$2.59M
Verandering (1 dag)
-11.00%
Verandering (1 jaar)
313.95%
Land
US
Handel Jupiter Neurosciences, Inc. (JUNS)

Categorie

Aandelsplitsingen voor Jupiter Neurosciences, Inc. (JUNS)
Het aandeel Jupiter Neurosciences, Inc. (symbool: JUNS) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 15, 2026.
Eén aandeel JUNS dat vóór Aug 15, 2026 werd gekocht, staat nu gelijk aan 0 aandelen JUNS.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE